145 studies found for:    "Neurotoxicity syndromes"
Show Display Options
Rank Status Study
1 Terminated A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity
Condition: Neurotoxicity Syndromes
Intervention: Drug: Dextromethorphan
2 Recruiting Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients
Condition: Neurotoxicity
Intervention: Drug: monosialoganglioside
3 Unknown  Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin
Conditions: Chemotherapeutic Agent Toxicity;   Colorectal Cancer;   Neurotoxicity
Interventions: Drug: FOLFOX regimen;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Genetic: gene expression analysis;   Genetic: protein expression analysis;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
4 Recruiting Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer
Condition: Neurotoxicity
Interventions: Drug: placebo;   Drug: GM;   Drug: oxaliplatin-based chemotherapy
5 Completed Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy
Conditions: Chemotherapeutic Agent Toxicity;   Colorectal Cancer;   Neuropathy;   Neurotoxicity
Interventions: Drug: calcium gluconate;   Drug: magnesium sulfate;   Other: placebo;   Drug: oxaliplatin
6 Completed
Has Results
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity Caused By Oxaliplatin in Patients Receiving Combination Chemotherapy for Stage II, Stage III, or Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery
Conditions: Colorectal Cancer;   Neurotoxicity
Interventions: Drug: calcium gluconate;   Drug: magnesium sulfate;   Other: placebo
7 Recruiting To Study the Individual Variants of Chemotherapy-Induced Neurotoxicity
Condition: Neurotoxicity Syndromes
Interventions: Other: Questionnaires;   Procedure: Peripheral nervous system examination;   Genetic: Whole Genome Sequence
8 Unknown  Study to Assess Prevention of Oxaliplatin-induced Neurotoxicity Through Vitamin D Pathway
Condition: Neurotoxicity
Intervention: Drug: Vitamin D3
9 Completed Protective Effect of Mangafodipir Against Oxaliplatin Neurotoxicity
Conditions: Neurotoxic Disorders;   Cancer
Intervention: Drug: Mangafodipir
10 Terminated Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer
Conditions: Cervical Cancer;   Endometrial Cancer;   Fallopian Tube Cancer;   Neurotoxicity;   Ovarian Cancer;   Primary Peritoneal Cavity Cancer;   Sarcoma
Interventions: Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: paclitaxel
11 Completed Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Conditions: Chemotherapeutic Agent Toxicity;   Neuropathy;   Neurotoxicity Syndrome;   Pain;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Drug: Carboplatin;   Drug: Glutathione;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Placebo;   Other: Quality-of-Life Assessment
12 Withdrawn Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy
Conditions: Fatigue;   Malignant Ovarian Mixed Epithelial Tumor;   Neuropathy;   Neurotoxicity Syndrome;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Pain;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Dietary Supplement: Acetyl-L-Carnitine Hydrochloride;   Other: Placebo;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment
13 Completed Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
Conditions: Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neurotoxicity Syndrome;   Pain;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Other: Cytology Specimen Collection Procedure;   Other: Pharmacological Study
14 Recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
Conditions: B Acute Lymphoblastic Leukemia;   Bone Necrosis;   Central Nervous System Leukemia;   Cognitive Side Effects of Cancer Therapy;   Neurotoxicity Syndrome;   Pain;   Testicular Leukemia;   Therapy-Related Toxicity;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
15 Active, not recruiting Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Conditions: Cognitive Side Effects of Cancer Therapy;   Fatigue;   Neurotoxicity Syndrome;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Therapy-Related Toxicity;   Waldenstrom Macroglobulinemia
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Biological: Rituximab;   Drug: Temsirolimus
16 Active, not recruiting Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
Conditions: Anxiety;   Fatigue;   Nausea and Vomiting;   Neurotoxicity Syndrome;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage I Ovarian Cancer;   Stage IA Fallopian Tube Cancer;   Stage IB Fallopian Tube Cancer;   Stage IC Fallopian Tube Cancer;   Stage II Ovarian Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIC Fallopian Tube Cancer;   Stage III Ovarian Cancer;   Stage III Primary Peritoneal Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Procedure: Assessment of Therapy Complications;   Other: Medical Chart Review;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
17 Completed Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Conditions: Chemotherapeutic Agent Toxicity;   Endometrial Adenocarcinoma;   Fallopian Tube Carcinoma;   Gastrointestinal Complication;   Malignant Ovarian Mixed Epithelial Tumor;   Neurotoxicity Syndrome;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Primary Peritoneal Carcinoma;   Stage II Ovarian Cancer;   Stage III Ovarian Cancer;   Stage IV Ovarian Cancer;   Undifferentiated Ovarian Carcinoma
Interventions: Drug: Paclitaxel;   Drug: Cisplatin
18 Active, not recruiting Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
Conditions: Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Fatigue;   Neurotoxicity Syndrome;   Obesity;   Stage I Uterine Corpus Cancer;   Stage II Uterine Corpus Cancer
Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
19 Active, not recruiting Brain Function in Young Patients Receiving Methotrexate for Acute Lymphoblastic Leukemia
Conditions: Childhood B Acute Lymphoblastic Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Cognitive Side Effects of Cancer Therapy;   Long-Term Effects Secondary to Cancer Therapy in Children;   Neurotoxicity Syndrome;   Psychological Impact of Cancer;   Untreated Childhood Acute Lymphoblastic Leukemia
Interventions: Procedure: Cognitive Assessment;   Procedure: Diffusion Tensor Imaging;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Procedure: Psychosocial Assessment and Care
20 Withdrawn Scopolamine Treatment for Patients With Organophosphate Poisoning
Condition: Neurotoxicity Syndromes
Intervention: Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years